Proteassemblin inhibitors constitute a distinctive subset of chemical compounds that intricately engage with the cellular machinery central to maintaining proper protein balance. This class of inhibitors specifically targets the proteassemblin complex, an intricate assembly responsible for orchestrating the assembly and disassembly of proteins within the cellular environment. The mode of action involves the binding of these inhibitors to distinct binding sites on the proteassemblin complex, thereby inducing a disruption in the delicate equilibrium that governs the turnover and organization of proteins. The consequences of this disruption extend across various cellular processes that rely on the precise regulation of protein dynamics. By interfering with proteassemblin's role in managing protein assembly, proteassemblin inhibitors can influence the formation of protein complexes critical for cellular function. This can subsequently lead to downstream effects on cellular processes such as signal transduction, gene expression, and metabolic pathways.
The intricate interplay between proteassemblin inhibitors and the complex molecular structure of the proteassemblin assembly is a subject of active investigation within the scientific community. Researchers delve into the three-dimensional structure of both the inhibitors and the proteassemblin complex, seeking to unravel the precise binding interactions and molecular conformational changes that underlie the inhibitory mechanism. Proteassemblin inhibitors hold significant promise as tools for probing the fundamental intricacies of cellular protein regulation. As researchers refine their understanding of these inhibitors and their effects, novel insights into the mechanisms governing protein homeostasis and cellular adaptation could emerge. The ongoing exploration of proteassemblin inhibitors provides a lens through which researchers can gain deeper insights into the intricate landscape of cellular biology, with potential implications for various scientific disciplines.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Reversible inhibitor of the proteasome's chymotrypsin-like activity, leading to cell cycle arrest and apoptosis. | ||||||
Carfilzomib | 868540-17-4 | sc-396755 | 5 mg | $40.00 | ||
Irreversible inhibitor of the proteasome's chymotrypsin-like activity, causing proteasomal dysfunction and cell death. | ||||||
Ixazomib | 1072833-77-2 | sc-489103 sc-489103A | 10 mg 50 mg | $311.00 $719.00 | ||
Oral proteasome inhibitor that inhibits the chymotrypsin-like activity, disrupting protein degradation pathways in cancer cells. | ||||||
Oprozomib | 935888-69-0 | sc-477447 | 2.5 mg | $280.00 | ||
Oral proteasome inhibitor with a mechanism similar to bortezomib, inducing apoptosis in cancer cells. | ||||||
Delanzomib, free base | 847499-27-8 | sc-396774 sc-396774A | 5 mg 10 mg | $160.00 $300.00 | ||
Potent proteasome inhibitor, primarily targeting the chymotrypsin-like activity, leading to apoptosis in cancer cells. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
Reversible proteasome inhibitor that blocks the chymotrypsin-like activity, leading to accumulation of ubiquitinated proteins. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $134.00 $215.00 $440.00 $496.00 | 19 | |
Irreversible inhibitor of the proteasome's chymotrypsin-like and trypsin-like activities, causing cell cycle arrest. | ||||||